Ichor Biologics specializes in the development of therapeutic monoclonal antibodies to treat infectious diseases. Our company has developed a platform for characterizing and isolating pathogen-specific antibodies from convalescent patients. This platform allows us to preserve neutralizing and non-neutralizing antibody functions, thereby increasing the likelihood of in-vivo efficacy. Our initial disease targets include viral infections, such as Hantaviruses and HBV.